Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial

By sjmartinez • April 1, 2025

Singh S, Nguyen JD, Fudman DI, Gerich ME, Shah SA, Hudesman D, McConnell RA, Lukin DJ, Flynn AD, Hwang C, Sprung B, Gaidos JKJ, Mattar MC, Rubin DT, Hashash JG, Metwally M, Ali T, Ma C, Hoentjen F, Narula N, Bessissow T, Rosenfeld G, McCurdy JD, Ananthakrishnan AN, Cross RK, Rodriguez Gaytan JR, Gurrola ES, Patel S, Siegel CA, Melmed GY, Weaver SA, Power S, Zou G, Jairath V, Hou JK. Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterol. 2025 Mar 31;12(1):e001615. doi: 10.1136/bmjgast-2024-001615. PMID: 40164445.

Tags: Cedars Sinai DoM, Crohn’s disease, Digestive Diseases, immunotherapy, inflammatory bowel disease, Publications

Related Posts

A CD57+ CD8 T cell subset links cytotoxic T cell cytotoxicity to fibrotic lung disease in systemic sclerosis

Sasaki T, Cao Y, Sowerby JM, Higashioka K, Marks KE, Elahee M, Kamiya M, Dellaripa PF, Ainsworth RI, Taylor KE, Bottini N, Wolters P, Kim[...]

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design

Plutzky J, Taub PR, Bhatt DL, Al Dhaybi O, Aroda VR, Basile JN, Bloch MJ, Budoff M, Busch RS, Buse JB, Cheung D, Christofides EA,[...]

Corrigendum to “Deep learning in fetal, infant, and toddler neuroimaging research”[Dev. Cognit. Neurosci. (2026), 101680]

Chin JH, Wyburd MK, Ayzenberg V, Bayet L, Bilgic B, Chen EM, Chen Y, Dineen Á, Fujita S, Liu J, Jun Y, Camacho MC, Zöllei[...]